Drug
Disitamab vedotin clinical trials
Also written RC48-ADC.
- studies test it
- 85
- open now
- 61
- in phase 3
- 14
- first study started
- 2015
Keep track of what changes. Save the disitamab vedotin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
83 studies that test it; most in 2023 (21); 2 more planned to start later
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 14 |
| 2023 | 21 |
| 2024 | 15 |
| 2025 | 9 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 13
- Phase 2
- 67
- Phase 3
- 14
- Phase 4
- 2
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 31 · Other 54
RemeGen Co., Ltd. (26) · Fudan University (4) · Qilu Hospital of Shandong University (4) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (4) · West China Hospital (4) · RenJi Hospital (4) · Seagen, a wholly owned subsidiary of Pfizer (3) · Tianjin Medical University Second Hospital (2)
Often tested with
Tested in the same studies.
Toripalimab (9) · Tislelizumab (6) · Cadonilimab (5) · Sintilimab (4) · Trastuzumab (3) · Capecitabine (3) · Bevacizumab (3) · Pembrolizumab (2)
Studies
Open first, then newest update. How each study uses disitamab vedotin is read from its arms, and is right about nine times in ten.
Testing it · 85
- Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerNot yet recruitingPhase 2Tianjin Medical University Second HospitalNCT07879469Written as Disitamab Vedotin and Toripalimab
- DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder CancerNot yet recruitingPhase 1Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07853053Written as Disitamab Vedotin
- Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial CarcinomaRecruitingPhase 3Peking University First HospitalNCT07498907Written as Disitamab Vedotin (RC48)
- A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2RecruitingPhase 3RemeGen Co., Ltd.NCT04400695Written as RC48-ADC
- A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 MutationNot yet recruitingPhase 1/2RemeGen Co., Ltd.NCT05745740Written as RC48-ADC
- A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingPhase 3RemeGen Co., Ltd.NCT07315750Written as Disitamab Vedotin
- First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingPhase 2Qilu Hospital of Shandong UniversityNCT06730373Written as Disitamab Vedotin
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingPhase 2Fudan UniversityNCT06649331Written as Disitamab Vedotin (RC48)
- A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid TumorsRecruitingPhase 1/2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06417554Written as SHR-A2102 + Disitamab Vedotin For Injection
- A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland CarcinomaNot yet recruitingPhase 2West China HospitalNCT07740993Written as disitamab vedotin
- Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)RecruitingPhase 2Tianjin Medical University Second HospitalNCT05837806Written as tislelizumab+disitamab-vedotin
- Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder CancerRecruitingPhase 2Shanxi Province Cancer HospitalNCT07646145Written as Disitamab Vedotin
- HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBCNot yet recruitingPhase 2/3West China HospitalNCT07608224Written as Disitamab Vedotin (RC48)
- HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUCNot yet recruitingPhase 2RenJi HospitalNCT07591805Written as Drug: Disitamab Vedotin
- RC48-ADC in HER2-low Advanced Breast CancerRecruitingNot applicableRenJi HospitalNCT05831878Written as Disitamab vedotin
- Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal CanceNot yet recruitingPhase 2Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07509424Written as disitamab vedotin, sintilimab, capecitabine
- A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07507526Written as Tunlametinib+PD-1 mAb
- Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II StudyRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07446452Written as Disitamab Vedotin (RC48)
- RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC FailureNot yet recruitingPhase 2/3Fudan UniversityNCT07366840Written as Disitamab Vedotin
- A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder CancerNot yet recruitingPhase 2Tongji HospitalNCT07279597Written as RC48-ADC + Toripalimab
See all 85 studies that test disitamab vedotin →
Given in every arm · 14 — disitamab vedotin is usual care beside what is tested
- Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder CancerNot yet recruitingPhase 2/3Tianjin Medical University Second HospitalNCT07756008Written as Disitamab Vedotin (RC48)
- A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2RecruitingPhase 2Seagen, a wholly owned subsidiary of PfizerNCT04879329Written as disitamab vedotin
- Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07717242Written as Disitamab vedotin
- Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBCRecruitingPhase 3Zhiquan HuNCT07693959Written as Disitamab Vedotin (RC48)
- Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBCNot yet recruitingPhase 2chenxuNCT07474064Written as Disitamab Vedotin
- DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast CancerRecruitingPhase 2RemeGen Co., Ltd.NCT06178159Written as Disitamab Vedotin Injection
- RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II StudyRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07065435Written as Disitamab Vedotin (RC48)
- Probiotics in Advanced Urothelial CarcinomaRecruitingPhase 2Sun Yat-sen UniversityNCT06904573Written as Disitamab vedotin
- Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ PatientsRecruitingPhase 1/2Zhejiang Cancer HospitalNCT06650332Written as Disitamab Vedotin
- To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast CancerRecruitingPhase 2RemeGen Co., Ltd.NCT06389006Written as Disitamab Vedotin for Injection
- A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT06233864Written as Disitamab Vedotin
- RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 AlterationsNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06185400Written as Disitamab Vedotin
- To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)RecruitingPhase 1RemeGen Co., Ltd.NCT05514158Written as RC48-ADC
- Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast CancerWithdrawnPhase 2RemeGen Co., Ltd.NCT06105008Written as Disitamab Vedotin
As the comparator · 1 — what is tested is compared with disitamab vedotin
Codes
What other systems call disitamab vedotin · ClinicalTrials.gg INT001915
- MeSH (NLM) C000722994disitamab vedotinOne source ClinicalTrials.gov
- UNII (FDA) RB3U3A1S27DISITAMAB VEDOTINOne source FDA
- NCI Thesaurus C169918Disitamab VedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722994 | disitamab vedotin | One source ClinicalTrials.gov |
| UNII (FDA) | RB3U3A1S27 | DISITAMAB VEDOTIN | One source FDA |
| NCI Thesaurus | C169918 | Disitamab Vedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.